Pharmaceuticals News and Research

RSS

Study looks at brain damage that occurs after stroke

Brain damage that occurs even days after a stroke, increasing stroke size and devastation, is the focus of researchers trying to identify new treatments.

1 Jun 2007

FDA approves Torisel (temsirolimus) for advanced kidney cancer

The U.S. Food and Drug Administration (FDA) hasapproved Torisel (temsirolimus) for the treatment of a certain type of advanced kidney cancer known as renal cell carcinoma.

1 Jun 2007

Mylan wins Omeprazole patent litigation

Mylan Laboratories Inc. has announced that the United States District Court for the Southern District of New York has ruled that Mylan's 10 mg and 20 mg omeprazole delayed-release capsules, which are the generic versions of AstraZeneca LP's Prilosec, do not infringe patents asserted against it by AstraZeneca.

1 Jun 2007

Mylan receives FDA approval for Azithromycin tablets

Mylan Laboratories Inc. ( NYSE:MYL ) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDAs) for Azithromycin Tablets, 250 mg and 500 mg.

1 Jun 2007

Mercury's link to heart disease

Heavy metals and other toxins have been linked to many human diseases, but determining exactly how they damage the body remains a mystery in many cases.

1 Jun 2007

Northwestern University researchers find drug reactions six years earlier than the FDA and drug companies

Northwestern University's Charles Bennett, M.D., is a super sleuth of potentially deadly prescription drug reactions.

30 May 2007

Office of Fair Trading's value-based pricing scheme is well-founded, but could increase overall NHS drug spend

A report by the Office of Fair Trading has recommended that pricing of drugs is based not on how much the drug costs to develop, but on the benefit that the drug can bring.

30 May 2007

Scientists study glutamate system in the brains of living people

A newly started research collaboration between Karolinska Institutet and AstraZeneca has already generated results.

30 May 2007

New class of compounds shows promise for cancer treatment

A new class of compounds developed by two University of Kentucky researchers shows promise as a nontoxic treatment of some cancers previously treated with toxic chemotherapy, the researchers report.

30 May 2007

Appetite-regulating hormones and peptides may be involved in the neurobiology of alcohol craving

Defined as a powerful urge to drink, or intense thoughts about alcohol, is an important contributor to the development and maintenance of alcoholism.

28 May 2007

Wake-up call to physicians caring for hepatitis B patients

Many patients with chronic hepatitis B are deficient in their understanding of the lifelong disease and often do not comply with the drug regimens necessary to control it, according to a new UCLA survey that suggests improved patient involvement in disease management decisions could be the key to fixing this problem.

28 May 2007

Tracing the path of depression

David Nutt, Professor of Psychopharmacology, said: "The development of one of these radioactive tracers to enable the study of noradrenaline and its related processes in those suffering depression is critical to our proper understanding of this disease.

27 May 2007

Study of Aripiprazole in adolescents with schizophrenia

In a six-week study in adolescents (13-17 years old) with schizophrenia, the Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company atypical antipsychotic aripiprazole demonstrated significant improvement compared to placebo on the primary efficacy endpoint, Positive and Negative Syndrome Scale (PANSS) Total Score.

24 May 2007

Clinical study results on bifeprunox for schizophrenia

Solvay Pharmaceuticals, Inc., Wyeth Pharmaceuticals and Lundbeck A/S presented clinical study results on bifeprunox, an investigational treatment for adult patients diagnosed with schizophrenia, at the 2007 annual meeting of the American Psychiatric Association.

24 May 2007

Lupin receives FDA approval for Ziprasidone Hydrochloride capsules

Lupin Pharmaceuticals has announced that on May 16, 2007 it received tentative approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Ziprasidone Hydrochloride Capsules 20mg, 40mg, 60mg and 80mg.

24 May 2007

Iloperidone shows promise for Akathisia

According to study results presented at the 2007 American Psychiatric Association annual meeting, iloperidone, an investigational atypical antipsychotic, was shown to have a favorable akathisia profile.

24 May 2007

Efficacy and safety of Aripiprazole as adjunctive therapy in major depressive disorder

In adults with major depressive disorder, adding aripiprazole to antidepressant therapy (ADT) resulted in significant improvement in the primary endpoint, the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score.

24 May 2007

Yoga shows promise in improving symptoms associated with depression, anxiety and epilepsy

Researchers at Boston University School of Medicine (BUSM) and McLean Hospital have found that practicing yoga may elevate brain gamma-aminobutyric (GABA) levels, the brain's primary inhibitory neurotransmitter.

23 May 2007

Pioneering skin researchers at the University of Leeds achieve international quality standard

The Skin Research Centre at the University of Leeds, which has led the way in the treatment of acne, eczema and other skin conditions, is the only University skin microbiology laboratory in the UK to receive the international quality standard ISO 17025.

22 May 2007

Lubiprostone may improve symptom relief rates in adults with irritable bowel syndrome with constipation

A new study demonstrated that the active ingredient in AMITIZA (lubiprostone), given 8 mcg twice a day, may improve symptom relief rates in adults with irritable bowel syndrome with constipation (IBS-C).

22 May 2007